Multiple Sclerosis Global Support Network News

"Your trusted source for the latest in MS news and information."

  • MS Info Hub
  • MS News

ECTRIMS 2017: Promising Work in Pediatric and Secondary Progressive Patients Is...

Gilenya (fingolimod) lowered relapse rates in children and adolescents with relapsing multiple sclerosis at a “magnitude” — almost 82 percent — never before seen in...

ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA...

The company expects to start enrollment before year's end MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - October 31, 2017) - Oryzon Genomics (MAD: ORY), a public clinical-stage biopharmaceutical...

Apitope ATX-1467 Completes Phase IIa Study Launches IPO

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat...

ECTRIMS 2017: Ibudilast Slows Loss of Brain Tissue in MS Patients,...

The Japanese company MediciNova‘s anti-inflammatory agent ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2...

ECTRIMS 2017: Ibudilast Significantly Slows Brain Atrophy for Progressive MS

Treatment with ibudilast (MN-166) slowed the rate of brain atrophy by 48% without inducing significant toxicity compared with placebo for patients with progressive multiple...

ECTRIMS 2017: Next-Gen S1P Receptor Modulator Shows Promise in MS

A next-generation sphingosine-1 phosphate (S1P) receptor modulator for multiple sclerosis was safe and effective compared with interferon beta-1a (Avonex), according to researchers here. In the...

ECTRIMS 2017: Ibudilast ‘Impressive’ for Progressive MS in Phase 2 Trial

The first-in-its class, small-molecule drug ibudilast (MN-166, MediciNova) is effective and safe for treating progressive multiple sclerosis (MS), new research suggests. In the multicenter phase...

ECTRIMS 2017: Phase 3 Trial Data Show Ozanimod Safe, Effective in...

  Ozanimod (RPC1063) was seen to lower relapse rates and reduce brain and spinal cord lesions among patients with relapsing multiple sclerosis (MS) participating in a...

ECTRIMS 2017: Alkermes ALKS 8700 Reports Initial 3 Month Of EVOLVE-MS-1...

Alkermes plc (NASDAQ: ALKS) today presented safety and gastrointestinal (GI) tolerability data from EVOLVE-MS-1, an ongoing open-label, two-year phase 3 safety study for ALKS 8700, a...

ECTRIMS 2017: Potential Progressive MS Treatment on Move in US and...

People with progressive multiple sclerosis are enrolling in a new and global Phase 3 study of MD1003, a high-dose biotin, “about as well as can...

Subscribe To Our Newsletter